Investments
661Funds
3Partners & Customers
10About National Institutes of Health
The National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services, is the nation's medical research agency making important medical discoveries that improve health and save lives.
National Institutes of Health Headquarter Location
9000 Rockville Pike
Bethesda, Maryland, 20892,
United States
301-496-4000
Expert Collections containing National Institutes of Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find National Institutes of Health in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
Medical Devices
66 items
https://mdic.org/membership/our-members/
Latest National Institutes of Health News
Jun 28, 2022
Rensselaer Polytechnic Institute researchers will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a low-dose, oral COVID antiviral drug that can be administered at home. “Our role in the project is to develop novel inhibitors of the two key proteases of the SARS-CoV-2 virus, called CLpro and PLpro, which are essential to the virus life cycle,” says researcher Gaetano Montelione , the Constellation Endowed Chair of Structural Bioinformatics. The team’s work will build upon Montelione’s previous research on COVID antiviral drug options. First, using bioinformatics, Montelione and his team found that a key protein from the hepatitis C virus closely resembles the coronavirus CLpro protease structure. Since several Food and Drug Administration (FDA)-approved drugs target the hepatitis C protease, the next step was to determine if any of those drugs would also bind and block proteases of SARS-CoV-2. In research published in Cell Reports, the team found that, out of the 10 hepatitis C drugs tested, seven suppressed the SARS-CoV-2 virus. Three of those drugs were acting not only on the main protease, CLpro, but on the PLpro protease, as well. Next, they discovered that, when combined with the polymerase inhibitor remdesivir, these drugs multiplied remdesivir’s antiviral activity by as much as tenfold. Those that only inhibit CLpro did not amplify remdesivir’s effect. “Inhibiting PLpro seems to be important,” says Christopher Cioffi , Thomas and Constance D’Ambra Endowed Chair of Organic Chemistry. “This induces synergy with other antivirals such as remdesivir, which is currently being used to treat people with COVID-19. Now, we will work toward making new and orally bioavailable PLpro inhibitors based on Montelione’s biophysical analysis. We will look at the structure of the protein’s active site and design molecules that fit into it and bind with optimal affinity.” CLpro will also be targeted. “One of the big challenges is that the target will evolve to escape the drug,” Montelione says. “This is particularly problematic with rapidly mutating viruses like COVID-19. To overcome that, we try to hit multiple targets. By hitting both CLpro and PLpro simultaneously, there is less likelihood of antiviral resistance.” It is hoped that the most promising COVID antiviral drug to come out of the AViDD centers will enter late-stage preclinical development. Industry partners will provide valuable resources to accelerate their movement through the product development pipeline. Drugs that are already FDA-approved for treating different diseases may be approved quicker for the treatment of COVID-19, as well. Share:
National Institutes of Health Investments
661 Investments
National Institutes of Health has made 661 investments. Their latest investment was in Reliant Glycosciences as part of their Grant on June 6, 2022.
National Institutes of Health Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/15/2022 | Grant | Reliant Glycosciences | $1.2M | Yes | 1 | |
6/9/2022 | Grant | Bright Uro | $2M | Yes | 2 | |
6/9/2022 | Grant - IV | Phase Genomics | $5.5M | Yes | 1 | |
6/7/2022 | Grant - II | |||||
5/24/2022 | Grant |
Date | 6/15/2022 | 6/9/2022 | 6/9/2022 | 6/7/2022 | 5/24/2022 |
---|---|---|---|---|---|
Round | Grant | Grant | Grant - IV | Grant - II | Grant |
Company | Reliant Glycosciences | Bright Uro | Phase Genomics | ||
Amount | $1.2M | $2M | $5.5M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 2 | 1 |
National Institutes of Health Fund History
3 Fund Histories
National Institutes of Health has 3 funds, including West Nile Grant.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
West Nile Grant | 1 | ||||
Dengue Grants - UC1 | |||||
Dengue Grants - UO1 |
Closing Date | |||
---|---|---|---|
Fund | West Nile Grant | Dengue Grants - UC1 | Dengue Grants - UO1 |
Fund Type | |||
Status | |||
Amount | |||
Sources | 1 |
National Institutes of Health Partners & Customers
10 Partners and customers
National Institutes of Health has 10 strategic partners and customers. National Institutes of Health recently partnered with IliAD Biotechnologies on April 4, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/26/2022 | Vendor | United States | ILiAD Biotechnologies , LLC collaborators for the National Institutes of Health grant include co-principal investigator Dr. Camille Locht , Inserm U1019 located at Institut Pasteur de Lille , ILiAD Biotechnologies , LLC 's wholly owned subsidiary , BioLyo Technologies , and The Commissariat à l'énergie atomique et aux energies alternatives department of Infectious disease models for innovative therapies . | 2 | |
2/7/2022 | Vendor | United States | Combined with a previous National Institutes of Health contract award of $ 24.4 million , this award positions Qorvo , Inc. to accelerate the production and market launch of multiple COVID testing solutions using a single platform . | 2 | |
1/19/2022 | Vendor | United States | 1 | ||
1/11/2022 | Licensee | ||||
1/3/2022 | Licensee |
Date | 4/26/2022 | 2/7/2022 | 1/19/2022 | 1/11/2022 | 1/3/2022 |
---|---|---|---|---|---|
Type | Vendor | Vendor | Vendor | Licensee | Licensee |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | ILiAD Biotechnologies , LLC collaborators for the National Institutes of Health grant include co-principal investigator Dr. Camille Locht , Inserm U1019 located at Institut Pasteur de Lille , ILiAD Biotechnologies , LLC 's wholly owned subsidiary , BioLyo Technologies , and The Commissariat à l'énergie atomique et aux energies alternatives department of Infectious disease models for innovative therapies . | Combined with a previous National Institutes of Health contract award of $ 24.4 million , this award positions Qorvo , Inc. to accelerate the production and market launch of multiple COVID testing solutions using a single platform . | |||
Sources | 2 | 2 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.